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To investigate the ability of convolutional neural networks (CNNs) to facilitate 
differentiation of oncocytoma from renal cell carcinoma (RCC) using non-invasive 
imaging technology.  
Methods 
 
Data were collected from 369 patients between January 2015 and September 2018. 
True labelling of scans as benign or malignant was determined by subsequent 
histological findings post-surgery or ultrasound-guided percutaneous biopsy. The data 
included 20,000 2D CT images. 
Data were randomly divided into sets for training (70%), validation (10%) and 
independent testing (20%, DataTest_1). A small dataset (DataTest_2) was used for 
additional validation of the training model. Data were divided into sets at the patient 
level, rather than by individual image. A modified version of the ResNet50V2 was used. 
Accuracy of detecting benign or malignant renal mass was evaluated by a 51% majority 














Test results from DataTest_1 indicate an area under the curve (AUC) of 0.973 with 
93.3% accuracy and 93.5% specificity. Results from DataTest_2 indicate an AUC of 
0.946 with 90.0% accuracy and 98.0% specificity when evaluation is performed image 
by image.  
There is no case in which multiple false negative images originate from the same 
patient. When evaluated with 51% majority of scans for each patient, the accuracy rises 
to 100% and the incidence of false negatives falls to zero. 
Conclusion 
CNNs and deep learning technology can classify renal tumour masses as oncocytoma 
with high accuracy. This diagnostic method could prevent overtreatment for patients 
with renal masses.  
 
Abbreviations  
Convolutional Neural Networks (CNN) 
Renal cell carcinoma (RCC) 
Ultrasound (US)  
Computed tomography (CT) 
Interquartile range (IQR) 
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The past two decades have seen an increase in diagnosed renal cell carcinomas (RCC) 
due to incidental detection of small renal tumours resulting from increased use of 
computed tomography (CT) scanning [1,2]. Most enhancing renal masses observed in 
adults are in fact RCCs; however, a significant proportion of such masses are benign 
(most commonly oncocytoma). Benign tumours cannot be distinguished from malignant 
tumours based solely on standard imaging technology [3]. 
In a recent surgical series of 228 patients who underwent partial or radical nephrectomy 
with lesions ≤4.0 cm, 26.3% of masses were found to be benign [4,5]. The relatively 
high proportion of patients with benign renal cortical neoplasms who underwent surgery 
in this sample group highlights the important role of new diagnostic technology in 
preventing overtreatment. 
Ultrasound-guided biopsy and computed tomography (CT)-guided biopsy are the two 
most commonly used methods of RCC diagnosis. The sensitivity of these methods is 
lower for biopsies of small masses (≤3.0 cm) than large masses (>3.0 cm) [6]. Biopsy 
sensitivity is limited by false negative results, which may be due either to the method’s 
failure to properly target a small renal mass or to the insufficient presence of cells, 
morphological overlap or cellular heterogeneity to clarify a diagnosis. Biopsies that fail 
to result in a diagnosis do not necessarily indicate that a mass is benign; rather, a 
majority of cases reveal a malignant diagnosis in repeated biopsies [7,8]. No radiologic 













specificity of the available biopsy technology [9]. MR and CT scans are not feasible 
diagnostic methodologies for oncocytoma because of overlap in the scan results of 
oncocytoma and RCC [10,11]. 
A system that enables precise automatic classification of CT images would be an 
important decision-making support tool for physicians providing diagnoses to their 
patients. In recent years, deep learning methods for convolutional neural networks 
(CNN) have contributed to several experiments that reported impressive results in the 
area of medical image analysis. Specifically, CNN and deep learning have been 
recognized for their ability to identify subtle yet indicative features that are difficult for 
the human eye to distinguish [12–15]. This study investigates the ability of a CNN to 
facilitate differentiation of oncocytoma from RCCs using non-invasive imaging 
technology.  
Materials and Methods 
The dataset for this study consisted of CT scans from 446 patients with an RCC or 
oncocytoma diagnosis. These data were extracted from a local pathological database; 
of the total, 67 of the scans were performed outside of the region and were therefore 
inaccessible, and ten of the scans were of such poor quality that the tumour could not 
be identified. The study sample therefore consists of 369 patient scans performed at six 
departments of radiology between January 2015 and September 2018. Nine of the 
scans were non-contrast phase only because the patients reported a contrast allergy, of 
them, six patients in training, two patients in DataTest_1, and one patient in validation. 












included a combination of non-contrast, arterial and venous phases. To ensure similarity 
of images, all scans were examined in the axial plane. Images were included in the 
analysis if they visualized a renal mass in any phase; otherwise, they were manually 
excluded. All scans reviewed manually by a radiologist and urologist and all scans with 
renal cysts or other renal lesions rather than renal tumor excluded from the cohort.The 
number of 2D images per patient ranged from 20–100, and the total sample consisted 
of more than 20,000 2D images. The slice thickness of images ranged from 1.5–5.0 
mm, depending on the local radiology department protocol, and the radiation dose was 
120 kilo voltage (kV) tube voltage. Original images with three colour channels of 512 x 
512-pixels were downscaled to 224 x 224 by the Keras API (using the PIL package, 
without cropping the images) for a better fit with the ResNet network structure. True 
labelling of the scans as benign or malignant was determined by subsequent 
histological diagnosis after surgery or renal mass biopsy. 
The total sample of scans was divided into categories for training (70% of scans, n = 
14,001 images from 259 patients), validation to check convergence during training (10% 
of scans, n = 238 images from 36 patients) and (DataTest_1) for independent testing of 
the trained model (20% of scans, n = 948 images from 74 patients). Each of the 
partitions (training, validation, and test) is seen as an independent data source during 
training. A set of 356 images collected from 12 patients in 2019 was used independently 
from the primary data (DataTest_2) for additional validation of the training model. A third 
set of data, including 1,737 images from 37 patients who underwent surgical treatment 













(DataTest_3) to analyse the ability of a CNN to prevent overtreatment of patients with 
renal masses. 
Random splitting of data was performed at the patient level to ensure that each group of 
images from an individual patient was included in the training set, one of the validation 
sets or one of the test sets. Following this initial categorization, each set was viewed as 
a collection of arbitrary images with no other patient information. Each image had a true 
classification as benign or malignant and there was no overlap of images from any 
given patient between image sets. 
 
The study approach does not include explicit segmentation (i.e., identifying image 
regions that show tumours); rather, it relies on the CNN’s ability to automatically identify 
the image features that are relevant for classification. Through training, the CNN learns 
to ignore anatomical features that are not related to malignancies and to add weight to 
features that are indicative of malignancies. The presence of a malignant tumour may 
create subtle changes in the surrounding anatomical structures. The CNN could 
theoretically add weight to those image features as well, but no evidence was found to 
indicate that this error occurred. 
A modified version of the ResNet50V2 [16] CNN was implemented with the TensorFlow 
and Keras software, running on standard and affordable hardware (AMD Ryzen 2700x 
CPU with 16GB RAM, GeForce GTX 980ti 4GB and 1050ti 2GB GPUs).  
The network hyper parameters included: 













 Binary Crossentropy as loss function 
 Learning Rate 0.00002 
 No regularization performed 
 No learning rate decay introduced 
 Ten epochs of training. 
 All weights were trainable during training and fine-tuning of the network. 
 
Quick convergence was expected due to the use of the RMSprop [17,18] loss 
optimization algorithm because averaged gradients were used. Therefore, a maximum 
of 20 epochs per network were trained prior to selection of the hyper parameters. Ten 
epochs were trained in the final model, because initial testing suggested that there were 
too many oscillations when more than ten epochs were trained without a decay applied 
to the learning rate. 
 
ResNet50V2 classifies images into multiple categories according to the object depicted; 
however, this study required a simple binary classification of benign or malignant. The 
final connected network layers could therefore be simple, and the convolutional layers 
were reused. Transferred learning from ResNet50V2 was used [19]; in other words, pre-
trained weights from Imagenet were applied because the initial weights for the 
convolutional layers and the fully connected layers for classification needed to be 













The accuracy for classifying a renal mass as benign or malignant was determined by a 
majority vote of individual image classifications. A 51% majority was used to determine 
each individual patient classification.  
This adaptation of ResNet50V2 was trained using 70% of the data, validated using 10% 
of the data, and tested using 20% of the data. As described above, a patient partitioning 
scheme was used rather than image partitioning. Neither phasic nor serial information 
from the renal CT images were used in the training, validation or test data; thus, single 
images were classified without relation to other images from the same patient. 
Therefore, mixed types of phasic images could be considered independently of one 
another. Furthermore, the network’s dense layers were simplified to reduce the chance 
of gaining bias or encoding of the image information into the network weights as 
opposed to learning features. 
As it appears above, we consider patients as our datapoints rather than the total 
amount of images. This is apparent in our method for dividing images into training, 
validation and test data sets and in our adaptation of ResNet50V2; see Figure 1 and 
[20] for more details and a comparison of the two possible methods (patients vs. images 
as datapoints). 
The complexity of the network is reduced considerably without loosing precision by 
removing the phasic and sequence (series) information and explicitly creating an image-














Three hundred patients (81%) were determined to have a malignant tumour, and 69 
patients (19%) were determined to have a benign tumour. The latter were oversampled 
in the training set to create a balanced dataset by sampling all patients in the benign 
training set until a 50:50 ratio was reached between benign and malignant patients. 
Oversampling does have the possibility of causing overtraining of the model, but any 
such overtraining would be shown by a large divergence of training and validation 
curves for accuracy and loss during training. Also, as the orientation and position of the 
anatomical structures doesn’t change for any image (the image is always in the same 
orientation and position) we choose not to apply data augmentation as the augmented 
data wouldn’t exist in the applied use case. Thirty percent of patients were male and 
70% were female. The median age for patients with a benign tumour was 68 years, 
(Interquartile range (IQR): 61–75), and the median age for patients with a malignant 
tumour was 65 years (IQR: 58–73). There was no significant difference in the size of 
benign and malignant tumours (p=0.56). The median size of benign tumours was 40.0 
mm (IQR: 23.0–54.0), and the median size of malignant tumours was 37.0 mm (IQR: 
16.0–65.0). Thirty-seven of the patients with benign tumours (54%) did not have renal 
mass biopsy and instead underwent surgical resection (radical or partial nephrectomy) 
either because the tumour was more than 4.0 cm or because the patient declined renal 
biopsy.  
The network training resulted in a quick convergence due to use of the RMSprop loss 
optimization algorithm and its averaged running gradients. High performance was 
achieved during training in both accuracy and loss within 3–4 epochs; however, there 













reduced following the eighth epoch, and signs of convergence were reduced as an 
increasing number of epochs were run (see Figures 2 and 3). These findings indicate 
that improved performance occurs if the learning rate is decayed after the fourth epoch 
to allow entry into a narrow minima. The fifth epoch was selected as the study model 
based on the convergence and minimized oscillations as discussed above. 
Analysis for DataTest_1  
DataTest_1 (Test data set) indicated an area under the curve (AUC) of 0.973 with 
93.3% accuracy and 93.5% specificity when evaluated image by image, indicating a 
converged neural net (see Figure 4). Though false negatives exist in the data, they do 
not originate from the same patient’s scans. When the data were evaluated based on a 
51% majority of individual image classifications for each patient as described above, the 
accuracy increased to 100% with zero false negatives. 
Analysis for DataTest_2  
DataTest_2 was used as an external validation set of newly collected data. This data 
set resulted in an AUC of 0.946 with 90.0% accuracy and 98.0% specificity when 
evaluated image by image (see Figure 5). As in the first data set, a small number of 
false negatives existed, but 100% accuracy was achieved when evaluated based on a 
51% majority of image classifications per patient.  
 













DataTest_3 (Collective/Aggregate data set) was used as an extra validation set and 
resulted in an AUC of 0.991 with 97.1% accuracy and 100.0% specificity when 
evaluated image by image (see Figure 6). As in previous sets, the accuracy increased 
to 100% when evaluated based on a 51% majority of image classifications per patient. 
Discussion 
This study’s findings demonstrate that it is possible to retrain ResNet50V2 and to use a 
CNN for automatic classification of renal tumours in multi-phasic CT images. The 
dataset used in this study is substantially larger than those of comparable studies, and 
the data used in test sets were independent of those used in training and validation sets 
[21,22] . In contrast to comparable studies, information about contrast phases and depth 
of each 2D image was discarded. This information was deemed inessential because it 
does not affect the accuracy of the results, and excluding this information from the data 
reduces the neural network complexity and thus the training time. Oversampling was 
used to obtain balanced training sets because there was approximately a 4:1 ratio of 
malignant to benign patients. 
Test results verified that overtraining was reduced by randomly dividing the 2D image 
sets into training and validation subsets by patient basis rather than by individual image. 
Classification using the trained model yielded 90.0–97.7% accuracy per image, and 
classification was consistently 100% accurate per patient when using a 51% majority of 
all 2D images in a given CT-scan. Overall, the method outlined in this study holds 
promise as an effective and efficient decision making support tool for medical experts 













The small deviation observed in the ROC curve for DataTest_2 is most likely based on 
variance in the data due to factors such as machine variance, patient variance or 
operator variance. This deviation is accounted for in the patient majority vote 
classification system. 
Analysis of the results from DataTest_1 and external validation of newly collected data 
in DataTest_2 indicate that the CNN learned the features of the CT images. Its 
performance in these tests is a significant improvement over existing models intended 
to classify CT images without the use of phasic and serial information. Further, the 
performance of the modified ResNet50V2 under conditions of reduced complexity and 
numerous convolutional layers suggests that the data is feature driven requiring feature 
extraction to provide data for classification, rather than complexity driven which would 
require added complexity (dense layers with many parameters) to represent the function  
required for classification. 
This study’s use of a CNN and deep learning technology to identify benign renal tumour 
masses with high accuracy could lead to a revolution in the diagnostic method in 
diagnostic methods for RCC. The high level of accuracy achieved in DataTest_3 
indicates that a CNN could be used to prevent overtreatment of patients. If the CNN 
system classifies a lesion as a benign renal tumour, then a biopsy can be offered to the 
patient to confirm the diagnosis. External validation of this algorithm using a large data 
set may eliminate the need for renal biopsies in the future. In the future, a web-based 
platform could potentially be developed to allow an urologist to upload patient data and 














Running the training of the network using data augmentation (rotation/flipping) with 
same network structure showed a decrease of AUC to 0.63 for DataTest_1 and AUC of 
0.85 for DataTest_2. Removing the oversampling and use data augmentation leads to a 
decrease of AUC to 0.60 for DataTest_1 and AUC of 0.56 for DataTest_2. For both 
tests the curve of loss and accuracy during training did not converge, (data not 
presented). This could suggest that the network uses complexity to represent a 
transformation of the image to convert it back to its original state, thus needed further 
complexity to get comparable results to those without data augmentation. Another area 
of exploration during clinical implementation and testing would be the use of brightness, 
saturation, and contrast data augmentation on regions of interest to normalize data for 
different imaging equipment or differences in imaging techniques. 
The limitations of this study include the relatively small number of patients included in 
the sample, as well as differences in slice thickness and phase of scan images based 
on protocols that differ different various departments of urology. Future research would 
ideally include a larger dataset drawn from all Danish hospitals to provide a critical 
assessment of the 100% classification accuracy observed in this study. Further 
research could also address the potential influence of regional differences in the 
historical development of CT scanners. Lastly, future research could produce heatmaps 
of the convolutional layers to provide an understanding of the anatomical structures and 
feature extraction required for the model to produce its classification. Such knowledge 
would allow for further optimization of the model and allow imaging techniques to be 













In conclusion, CNNs and deep learning technology were used to identify renal tumour 
masses as oncocytoma in CT images with 90.0–97.7% accuracy by image and up to 
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Figure 1: Original ResNet50V2 structure compared to the version used for this study to 



















































































Figure 6: ROC curve analysis of DataTest_3 results when evaluated image by image 
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